Opioids Flashcards

1
Q

Give an overview on opioids

A

– Opioid actions include analgesia, respiratory depression, euphoria and sedation…
• Led to discovery of receptor subtypes.
– Morphine analogues…
• Agonists - morphine, diamorphine (heroin), codeine.
• Antagonists – naloxone. Also used in the treatment of addiction.
– Synthetic derivatives: pethidine, fentanyl, methadone.

– Opioid applies to any drug (natural or synthetic) that mimics endogenous opioid peptides by causing prolonged activation of opioid (usually m receptors). Opiate refers to synthetic morphine-like drugs without a peptide structure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are pethidine and fentanyl?

A

phenylpiperidine derivatives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are endogenous opioids?

A

Endogenous opioids are derived from large precursor molecules – encoded for by different genes: β-endorphin, enkephalins, dynorphins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe opioid receptors

A

Opioid receptors are G-protein coupled linked to opening K+ channels which cause hyperpolarization and closing Ca2+ channels inhibiting transmitter release.

Receptors were postulated to mediate the dysphoric (anxiety, hallucinations, bad dreams) produced by some opiates but they are not true opioid receptors as not blocked by naloxone and acted on by other psychotomimetic drugs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do opioids produce their effect?

A

Most of the clinically relevant opioid agonists bind to the mu-opioid (MOP) receptors, within the central and peripheral nervous system. This subsequently induces cellular hyperpolarisation and prompts analgesia, by blocking pain signals travelling to the brain

Agonists: Bind to the receptor and stimulate physiological activity.

Partial agonists: Bind to the receptor but do not produce maximum stimulation.

Antagonists: Have no intrinsic pharmacological effect, but bind to the receptor and can block the action of an agonist.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

name the 4 opioid receptor types

A

Three classical receptors mu, delta and kappa and a forth.

It not only shared homology but was also a classical Gi/Go coupled 7 transmembrane spanning receptor and it turned out to have an endogenous ligand that shared sequence homology with classical endogenous opioid peptide ligands that had already been identified as acting at the mu, delta and kappa opioid receptors - MOP, DOP, KOP and NOP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The four receptors have four families of endogenous ligands that act at them. Describe them

A

POMC that gives rise to b-endorphin, Proenkephalin producing at least four distinct enkephalins, Prodynorphin producing two dynorphins and two neo-endorphins and pronociceptin that produces nociceptin and two other biologically active compounds, one nocistatin which is an antagonist at the NOP receptor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

where are opioid receptors found in the brain?

A

There is widespread expression in many brain regions, including the rostral to caudal cortex, motor regions such as the caudate, limbic structures such as the amygdala, stria terminalis, reward areas such as the nucleus accumbens and of course pain processing structures such as the thalamus and the colliculi.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

name the pharmacological effects of opioids

A
Analgesic
euphoria 
respiratory depression 
pupil constriction 
cough reflex
GI tract 
nausea and vomiting (Caused by stimulation of chemoreceptor trigger zone on d (CTZ) and vomiting centre (m) – often need to give an anti-emetic alongside opioid analgesics)

Morphine can also cause histamine release from mast cells with vasodilation and itching (often needing an antihistamine to be prescribed).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe how opioids mediate analgesic effects

A
  • Opioids effective in acute and chronic pain although of limited use in neuropathic pain (neurological disease of sensory pathways).
  • They can block pain at 3 different levels; supraspinal, spinal and peripheral.
  • Supraspinal effect probably reflects an effect on the limbic system – reduces the perception of pain (this area would also be responsible for euphoria).
  • Morphine antinociceptive and reduces affective component of pain. Action at limbic system (which part of brain?)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how can opioids cause respiratory depression?

A
  • Mediated by m receptors.
  • Decrease in sensitivity of respiratory centre to PCO2 levels.
  • Commonest cause of death in acute opiate poisoning.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is a diagnostic feature in opiate poisoning?

A

pupil constriction which gives rise to “pinpoint” pupils.

Other causes of respiratory depression & coma cause pupil dilatation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what do opioids do to the GI tract?

A
  • Reduced motility therefore constipation and reduced absorption of other drugs.
  • Contraction of gall bladder and constriction of biliary sphincter – can increase pain in patients with gall stones.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

describe tolerance

A

– Higher dose needed to exert same effect
– Tolerance rapidly develops to most pharmacological effects. However, there is less tolerance to GI effects.

Tolerance and dependence are problems in addicts but not in clinical situation. In terminally ill patients increased dose is usually required because of increasing pain and not tolerance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what happens when morphine is abruptly withdrawn

A

Due to physical dependance, abrupt withdrawal of morphine after chronic ingestion causes increased­ irritability, loss of weight, body shakes, writhing, jumping & aggression.

– Gradual withdrawal less intense reaction.
– Physical dependence rarely progresses to addiction (psychological dependence).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe the pharmacokinetic properties of morphine

A

– Morphine slowly and erratically absorbed.
– Slow release preparations to ­ action.
– Patient controlled, pumps to allow infusion ‘on demand’ - upper dose set.

17
Q

describe the mechanism of action of opioids

A

Opioid receptors m, d, k cause inhibition…

  1. ­ K+ channel opening, hyperpolarization.
  2. ¯ opening of voltage-gated Ca2+ channels.
  3. Reduce neuronal excitability (K+) and reduce neurotransmitter release (Ca2+).
  4. Inhibition of adenylyl cyclase, decrease cAMP, PKA.

Acts both postsynaptically and presynaptically to block pain signals from going to the brain by reducing glutamate as well as hyperpolarising neurones to block the signal.

18
Q

give an overview on diamorphine (MOP)- STRONG

A
  • Used as analgesic in UK
  • Tissue injury, tumour growth
  • More lipid soluble than morphine and has more rapid onset when given IV.
  • Small epidural doses of diamorphine are being used to control severe pain.
19
Q

give an overview of pethidine (MOP)- STRONG

A
  • Favoured for analgesia during labour as no ¯ in uterine contraction.
  • Rapid onset of action but short duration of action.
  • Pethidine slowly eliminated in the neonate, naloxone may be needed to reverse respiratory depression.
  • Metabolized by liver – at high doses a toxic metabolite is formed (norpethidine) which can cause convulsions.
  • Pethidine interacts with MAOIs – delirium, convulsions & respiratory depression.
20
Q

describe fentanyl (MOP)-STRONG

A
  • More rapid onset and shorter duration than morphine.
  • Can be given transdermally for chronic pain.
  • Main uses: anaesthesia, patient-controlled infusion, severe pain.
21
Q

describe buprenorphine- STRONG

A
  • Partial agonist at m receptors.
  • Slow onset of action but greater duration of action than morphine – may cause prolonged vomiting.
  • Given sublingually.
  • Difficult to antagonise effects with naloxone as dissociates very slowly from receptors.
22
Q

describe codeine- WEAK

A
  • Readily absorbed, only 20% potency of morphine.
  • Used as oral analgesic for mild pain.
  • No euphoria, constipation.
  • Low affinity for opioid receptors but about 10% of the drug is demethylated to morphine which is responsible for analgesic effect.
23
Q

describe dextropropoxyphene- WEAK

A

• Half as potent as codeine often used in conjunction with paracetamol and aspirin although little evidence that combination is better than NSAID alone.

24
Q

describe dihydrocodeine- WEAK

A

Useful in 10% of population who are resistant to codeine – lack demethylating enzyme converting codeine to morphine.

25
Q

describe tramadol

A
  • Weak mu opioid agonist and weak NA reuptake inhibitor.
  • Used for postoperative pain.
  • Effective analgesic and better tolerated than most opiates used for moderate to severe pain.

Naloxone, antagonist which do not cross BBB for opioid constipation.

26
Q

what are the causes of increasing prescription opioid overdose?

A
  • Increase heroin use in US.
  • Increase use of pain killers.
  • Big black market of prescription medication without MD supervision.
  • Change in attitude of health care providers.
27
Q

what are the truths about chronic pain treatment and addiction?

A
  • “Addiction” among chronic pain patients varies (3%-40%) depending differences in treatment duration, assessment of addiction.
  • Properly managed short term medical use of opioid analgesics rarely cause addiction but physical dependence is more common.
  • Risk of addiction increases when used in other ways as prescribed (high doses, different route of administration, combined with alcohol, history of comorbid psychiatric disorders, genetic polymorphisms, age (adolescents, older adults).
28
Q
  • Biggest hurdle: Maintenance of drug-free state as 70% relapse.
  • Current pharmacotherapy ineffective at maintaining this.
  • Physical withdrawal symptoms decrease over time whereas emotional withdrawal symptoms persist for months.
  • 40% co morbidity between opioid addiction and anxiety, depression.
  • Impairment of social behaviour in heroin abstinent individuals.
A

MAD

29
Q

how do opioids induce rewarding effects?

A

This has been proven in knockout studies with mice. Opioids have been shown to increase dopamine release in mice. MOP knockout mice have reduced dopamine release upon opioid administration.

30
Q

How do opioids act at a molecular level?

A

Normally a ligand will bind to the opioid receptor to induce a response by causing potassium channels to open. Upon repeated activation of the opioid receptor, kinases (PKA/PKC) phosphorylate the receptor. This causes desensitization – upon further ligand binding, no further pharmacological effects occur.

Following chronic ligand binding to the opioid receptors, phosphorylation of the receptors induces arrestin recruitment and internalization of the receptors inside the cell. These will either be degraded by lysosomes or recycled back to the surface membrane.

Some opioid drugs induces internalisation and desensitization, some drugs only induce one or the other.

31
Q

describe the mechanism of dependence (homeostatic compensatory neuroadaptation)

A
  • Upon chronic administration of the drug, the opioid receptors (Gi) become desensitized.
  • This causes an increase in cAMP, particularly in the noradrenergic pathway in the brain causing an increase in NA release.
  • The surge in NA release is the causes of withdrawal symptoms.
  • Drug abusers have decreased frontal cortex activity (hypoactivated) and decreased D2 striatal binding.
  • Addiction strengths the associations between the amygdala and hippocampal region (reward region) which increases the salience to take the drug.
32
Q

is the endogenous opioid system involved in cocaine addictions?

A

Having confirmed with KO mouse technology that the role of the Mop and KOP system in positive reinforcement we hypothesised that the MOP and KOP system is central to the motivational properties of all drugs of abuse and not only opioids. There is a large body of literature suggesting that this is the case with alcohol addiction and indeed naltrexone, a non-selective opioid receptor antagonist is used for the treatment of this condition. Cocaine both increases dopamine (motivation) but also increases the levels of MOP receptor (pleasure).

From all these studies, we can conclude that both MOP and KOP system play a central opposing regulatory roles in the motivational effect effects of cocaine. Cocaine activates the MOP system which is involved in the positive reinforcement, hedonic (pleasurable) effect of cocaine by enhancing dopamine release in the nucleus accumbens which is evident in non-dependent individuals. Cocaine also activates the dynorphin/KOP system which has the opposite effect of MOP. It reduces/opposes the +reinforcement, the rewarding and sensitisation effect of cocaine by inhibiting the release of dopamine in the nucleus accumbens. That could trigger the transition from an active +positive reinforcement effect of cocaine in non-dependent individuals to a supressed positive reinforcement effect of the drug which occurs during dependence. In addition, the activation of the KOP system by cocaine also activates the negative reinforcement by inducing dysphoria, stress and anxiety which will be driving the SA of the drug. In other words, all these studies suggest that activation of the KOP system by cocaine plays a central role for the transition from +reinforcement, impulsive to a -reinforcement compulsive cocaine SA. This implies that mixed MOP/KOP antagonist could be beneficial for the treatment of cocaine dependence and the prevention of relapse. Indeed a recent clinical trial using a buprenorphine (Kappa antagonist) and naltrexone (non-selective opioid antagonist) improved compliance compared to naltrexone alone in cocaine addicts supporting the therapeutic potential of KOP antagonists.

33
Q

what is the role of endogenous opioids in addiction?

A
  • Mu agonists are reinforcing and cocaine reinforcement is modulated by opioid antagonists.
  • Mu antagonists are effective in limiting craving and relapse.
  • Injections of opioids into the VTA generate self-administration.
  • Mu opioids facilitate intracranial self-stimulation.
  • Mu opioid receptor knockout mice show loss of addictive responses to opioids, alcohol, cannabinoids and nicotine.
  • Proenkephalin knockout mice show loss of addictive response to cannabinoids and nicotine.
  • Alcohol and nicotine induce the release of endogenous opioids – treatment of alcohol addiction using opioid receptor antagonists.
  • Cocaine induces MOP and KOP upregulation which is persistent.
34
Q

give evidence of how genetics play a role in opioid addiction

A

A118G SNP (Asn to Asp) of MOP and heroin addiction